Vaccinex Shares Tumble 63% On Nasdaq Delisting

Dow Jones12-18

By Katherine Hamilton

Vaccinex shares dropped Tuesday after the company said it is being delisted from the Nasdaq capital market after falling short of the minimum stockholder equity required for listing.

The stock lost about two-thirds of its value on Tuesday. Shares are down 87% to $1.37 this year.

The biotechnology company, which specializes in treating neurodegenerative diseases, said Nasdaq gave notice on Monday it was delisting the company. Vaccinex has previously said it did not maintain the minimum $2.5 million in stockholders' equity required to be listed on the market.

Trading in Vaccinex's common stock will be suspended starting on Wednesday when the market opens, the company said.

After its delisting from Nasdaq, Vaccinex said it expects its stock will be on the OTC Markets Group under the symbol VCNX.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 17, 2024 11:55 ET (16:55 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492960184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492960184","market":"hk","top_or_hot":-1,"title":"Vaccinex Shares Tumble 63% On Nasdaq Delisting","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Vaccinex shares dropped Tuesday after the company said it is being delisted from the Nasdaq capital market after falling short of the minimum stockholder equity required for listing. \n</p>\n<p>\n  The stock lost about two-thirds of its value on Tuesday. Shares are down 87% to $1.37 this year. \n</p>\n<p>\n  The biotechnology company, which specializes in treating neurodegenerative diseases, said Nasdaq gave notice on Monday it was delisting the company. Vaccinex has previously said it did not maintain the minimum $2.5 million in stockholders' equity required to be listed on the market. \n</p>\n<p>\n  Trading in Vaccinex's common stock will be suspended starting on Wednesday when the market opens, the company said. \n</p>\n<p>\n  After its delisting from Nasdaq, Vaccinex said it expects its stock will be on the OTC Markets Group under the symbol VCNX. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 11:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccinex Shares Tumble 63% On Nasdaq Delisting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccinex Shares Tumble 63% On Nasdaq Delisting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 00:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Katherine Hamilton \n\n\n \n\n\n  Vaccinex shares dropped Tuesday after the company said it is being delisted from the Nasdaq capital market after falling short of the minimum stockholder equity required...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492960184","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492960184","pubTimestamp":1734454500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vaccinex shares dropped Tuesday after the company said it is being delisted from the Nasdaq capital market after falling short of the minimum stockholder equity required for listing.The stock lost about two-thirds of its value on Tuesday. Shares are down 87% to $1.37 this year.The biotechnology company, which specializes in treating neurodegenerative diseases, said Nasdaq gave notice on Monday it was delisting the company. Vaccinex has previously said it did not maintain the minimum $2.5 million in stockholders' equity required to be listed on the market.Trading in Vaccinex's common stock will be suspended starting on Wednesday when the market opens, the company said.After its delisting from Nasdaq, Vaccinex said it expects its stock will be on the OTC Markets Group under the symbol VCNX.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4112":"金融交易所和数据","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4568":"美国抗疫概念",".IXIC":"NASDAQ Composite","VCNX":"Vaccinex Inc."},"translate_title":"纳斯达克退市后Vaccinex股价暴跌63%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"NQmain":1,"NDAQ":1,"VCNX":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Vaccinex shares dropped Tuesday after the company said it is being delisted from the Nasdaq capital market after falling short of the minimum stockholder equity required for listing. \n\n\n  The stock lost about two-thirds of its value on Tuesday. Shares are down 87% to $1.37 this year. \n\n\n  The biotechnology company, which specializes in treating neurodegenerative diseases, said Nasdaq gave notice on Monday it was delisting the company. Vaccinex has previously said it did not maintain the minimum $2.5 million in stockholders' equity required to be listed on the market. \n\n\n  Trading in Vaccinex's common stock will be suspended starting on Wednesday when the market opens, the company said. \n\n\n  After its delisting from Nasdaq, Vaccinex said it expects its stock will be on the OTC Markets Group under the symbol VCNX. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 11:55 ET (16:55 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492960184"}